SymBio Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Tokyo Japan (2005)

Organization Overview

First Clinical Trial
2006
NCT00389051
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SymBio Pharmaceuticals